interestingly COAST reports ph3 first in early Q2 2025 which is trial with eyelea - eyelea has $6B+ in sales and from memory OPT p2b in comparison to eyelea was better result than against lucentis (which only does about $1.5B of sales p.a)
So all in all - it’s the first trial result which will make or break this company
interestingly COAST reports ph3 first in early Q2 2025 which is...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
0.005(1.32%) |
Mkt cap ! $473.9M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 38.0¢ | $142.7K | 370.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 49829 | 38.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 87450 | 3 |
View Market Depth
| Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |